Limited U.S. Price Increases

We acknowledge our role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:

  • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
  • Government policies; and
  • Evolving trends in the marketplace.

Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing.

Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022.

The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016.

Clear Rationale for Pricing

at the time of launch of a new medicine

Continued Transparency in the U.S.

around our pricing decisions

MAT-US-2017360-v3.0-12/2022